These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 18396690)
1. [Expression and significanc of ERbeta and HER2 in breast cancer]. Yang SE; Li X Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):767-8. PubMed ID: 18396690 [No Abstract] [Full Text] [Related]
2. Detection of an elevated HER2 expression in MCF-7 breast cancer cells overexpressing estrogen receptor beta1. Lattrich C; Juhasz-Boess I; Ortmann O; Treeck O Oncol Rep; 2008 Mar; 19(3):811-7. PubMed ID: 18288420 [TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast. Rody A; Diallo R; Poremba C; Speich R; Wuelfing P; Kissler S; Solbach C; Kiesel L; Jackisch C Oncol Rep; 2004 Oct; 12(4):695-9. PubMed ID: 15375487 [TBL] [Abstract][Full Text] [Related]
4. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression. Park SS; Kim SW Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359 [TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer? Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124 [TBL] [Abstract][Full Text] [Related]
6. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. Hussein MR; Abd-Elwahed SR; Abdulwahed AR Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077 [TBL] [Abstract][Full Text] [Related]
7. Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer. Borgquist S; Holm C; Stendahl M; Anagnostaki L; Landberg G; Jirström K J Clin Pathol; 2008 Feb; 61(2):197-203. PubMed ID: 18223096 [TBL] [Abstract][Full Text] [Related]
8. PPARgamma expression in breast cancer: clinical value and correlation with ERbeta. Papadaki I; Mylona E; Giannopoulou I; Markaki S; Keramopoulos A; Nakopoulou L Histopathology; 2005 Jan; 46(1):37-42. PubMed ID: 15656884 [TBL] [Abstract][Full Text] [Related]
9. The significance of c-erbB-2 overexpression and p53 expression in patients with axillary lymph node--negative breast cancer: a tissue microarray study. Ko SS; Na YS; Yoon CS; Park JY; Kim HS; Hur MH; Lee HK; Chun YK; Kang SS; Park BW; Lee JH Int J Surg Pathol; 2007 Apr; 15(2):98-109. PubMed ID: 17478762 [TBL] [Abstract][Full Text] [Related]
10. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Roger P; Sahla ME; Mäkelä S; Gustafsson JA; Baldet P; Rochefort H Cancer Res; 2001 Mar; 61(6):2537-41. PubMed ID: 11289127 [TBL] [Abstract][Full Text] [Related]
11. Relationship between c-erbB-2 oncoprotein, epidermal growth factor receptor, and estrogen receptor expression in patients with ductal breast carcinoma. Association with tumor phenotypes. Harłoziñska A; Bar JK; Wenderski R; Bebenek M In Vivo; 1996; 10(2):217-22. PubMed ID: 8744803 [TBL] [Abstract][Full Text] [Related]
12. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Steinman S; Wang J; Bourne P; Yang Q; Tang P Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367 [TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients. Savinov AY; Remacle AG; Golubkov VS; Krajewska M; Kennedy S; Duffy MJ; Rozanov DV; Krajewski S; Strongin AY Cancer Res; 2006 Mar; 66(5):2716-24. PubMed ID: 16510592 [TBL] [Abstract][Full Text] [Related]
14. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization. Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295 [TBL] [Abstract][Full Text] [Related]
15. Distinct mRNA, protein expression patterns and distribution of oestrogen receptors alpha and beta in human primary breast cancer: correlation with proliferation marker Ki-67 and clinicopathological factors. Jarzabek K; Koda M; Kozlowski L; Mittre H; Sulkowski S; Kottler ML; Wolczynski S Eur J Cancer; 2005 Dec; 41(18):2924-34. PubMed ID: 16289616 [TBL] [Abstract][Full Text] [Related]
16. The estrogen receptors alpha, beta, and beta cx. Shaaban AM; Speirs V Clin Cancer Res; 2005 Nov; 11(22):8222; author reply 8222-3. PubMed ID: 16299256 [No Abstract] [Full Text] [Related]
17. AKT signaling pathway in invasive ductal carcinoma of the breast: correlation with ERa, ERβ and HER-2 expression. Wang X; Yi L; Zhu Y; Zou J; Hong Y; Zheng W Tumori; 2011; 97(2):185-90. PubMed ID: 21617713 [TBL] [Abstract][Full Text] [Related]
18. Quantitative profile of estrogen receptor variants/isoforms in Taiwanese women with breast cancer. Hsiao WC; Cho WC; Lin PW; Lin SL; Lee WY; Young KC Eur J Surg Oncol; 2006 Jun; 32(5):492-7. PubMed ID: 16551498 [TBL] [Abstract][Full Text] [Related]
19. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence. Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759 [TBL] [Abstract][Full Text] [Related]
20. [Expression and significance of Rab5a and APPL1 in breast cancer]. Chen Q; Liu WY; Zhao Z; Xie Y; Han BS Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):838-41. PubMed ID: 23291133 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]